Donald Craig Allred
#167,436
Most Influential Person Now
Donald Craig Allred's AcademicInfluence.com Rankings
Donald Craig Allredbiology Degrees
Biology
#13645
World Rank
#17200
Historical Rank
Pathology
#203
World Rank
#335
Historical Rank
Download Badge
Biology
Why Is Donald Craig Allred Influential?
(Suggest an Edit or Addition)Donald Craig Allred's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. (2006) (3857)
- American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. (2010) (3403)
- Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. (2014) (3308)
- Prognostic and predictive factors in breast cancer by immunohistochemical analysis. (1998) (2159)
- Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. (1999) (2062)
- Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. (2013) (1551)
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. (2007) (1419)
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. (2010) (1260)
- Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. (2000) (1104)
- Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition (2012) (998)
- Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. (2003) (811)
- Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. (1993) (807)
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). (2010) (760)
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. (2010) (668)
- Postmenopausal hormone therapy: an Endocrine Society scientific statement. (2010) (610)
- Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. (2005) (500)
- Breast cancer. Clinical practice guidelines in oncology. (2009) (498)
- HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. (1992) (477)
- Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. (2011) (457)
- Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. (1992) (421)
- p53 is mutated in a subset of advanced-stage prostate cancers. (1993) (401)
- Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. (1998) (364)
- Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. (1989) (361)
- Aberrant Subcellular Localization of BRCA1 in Breast Cancer (1995) (336)
- How to use prognostic factors in axillary node-negative breast cancer patients. (1990) (331)
- Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study (2004) (302)
- Ductal Carcinoma In situ and the Emergence of Diversity during Breast Cancer Evolution (2008) (301)
- HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. (1998) (301)
- Breast cancer outcome and predictors of outcome: are there age differentials? (1994) (298)
- Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. (1992) (287)
- Image-detected breast cancer: state of the art diagnosis and treatment. (2005) (277)
- Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. (1999) (267)
- Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. (1991) (263)
- The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. (2006) (248)
- A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. (2000) (241)
- Location of BRCA1 in Human Breast and Ovarian Cancer Cells (1996) (240)
- Neoadjuvant trastuzumab induces apoptosis in primary breast cancers (2005) (239)
- Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. (1999) (231)
- Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance) (2017) (218)
- Breast Cancer Patients with Progesterone Receptor PR-A-Rich Tumors Have Poorer Disease-Free Survival Rates (2004) (215)
- HER2 testing in breast cancer: NCCN Task Force report and recommendations. (2006) (205)
- An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ (2009) (202)
- Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. (2012) (200)
- Issues and updates: evaluating estrogen receptor-α, progesterone receptor, and HER2 in breast cancer (2010) (197)
- Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. (2005) (192)
- Ductal carcinoma in situ: terminology, classification, and natural history. (2010) (190)
- Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. (2003) (189)
- Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. (1990) (184)
- Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. (1997) (165)
- bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. (1997) (164)
- Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. (1993) (162)
- Loss of Par3 promotes breast cancer metastasis by compromising cell–cell cohesion (2012) (160)
- Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer. (2012) (151)
- Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. (2017) (145)
- The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer. (2008) (144)
- NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. (2009) (139)
- PIK3CA mutations in in situ and invasive breast carcinomas. (2010) (137)
- bcl‐2 and apoptosis in lymph node positive breast carcinoma (1998) (136)
- Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. (2010) (133)
- Invasive breast cancer. (2011) (133)
- Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. (2002) (131)
- Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. (2003) (130)
- Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays. (2010) (129)
- Prognostic and predictive value of p53 and p21 in breast cancer (2004) (126)
- Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. (2000) (125)
- Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. (2012) (120)
- p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. (1994) (118)
- Differential Expression of the Early Lung Cancer Detection Marker, Heterogeneous Nuclear Ribonucleoprotein-A2/B1 (hnRNP-A2/B1) in Normal Breast and Neoplastic Breast Cancer (2001) (107)
- Insulin receptor expression and clinical outcome in node-negative breast cancer. (1997) (104)
- Alterations of gene expression in the development of early hyperplastic precursors of breast cancer. (2007) (86)
- Human primary ductal carcinoma in situ (DCIS) subtype‐specific pathology is preserved in a mouse intraductal (MIND) xenograft model (2011) (85)
- Development of Standard Estrogen and Progesterone Receptor Immunohistochemical Assays for Selection of Patients for Antihormonal Therapy (2007) (82)
- The p53 tumor suppressor gene in breast cancer (2004) (78)
- Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients. (2000) (72)
- Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response (1998) (70)
- Commentary: hormone receptor testing in breast cancer: a distress signal from Canada. (2008) (70)
- Role of the Estrogen Receptor Coactivator AIB 1 ( SRC-3 ) and HER-2 / neu in Tamoxifen Resistance in Breast Cancer (2003) (68)
- Testing for erbB-2 by immunohistochemistry in breast cancer. (2000) (67)
- Epstein-Barr virus infection is associated with p53 accumulation in nasopharyngeal carcinoma. (1998) (66)
- Adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer. (1996) (65)
- Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women. (2005) (64)
- Biological Features of Premalignant Disease in the Human Breast (2000) (64)
- Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot study (2004) (64)
- Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. (1994) (61)
- Prognostic significance of p53 gene alterations in node-negative breast cancer (2004) (60)
- Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies (2005) (57)
- The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. (1996) (57)
- Expression of HER-2/neu oncoprotein in human breast cancer: a comparison of immunohistochemical and western blot techniques. (1992) (54)
- Pathologic outcomes of nonmalignant papillary breast lesions diagnosed at imaging-guided core needle biopsy. (2012) (54)
- Prediction of Node-Negative Breast Cancer Outcome by Histologic Grading and S-Phase Analysis by Flow Cytometry: An Eastern Cooperative Oncology Group Study (2192) (2001) (53)
- Molecular genetic studies of early breast cancer evolution (2004) (50)
- The Relevance of Mouse Models to Understanding the Development and Progression of Human Breast Cancer (2008) (49)
- Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer. (1997) (48)
- Differential antigen preservation during tissue autolysis. (1991) (47)
- Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience. (2005) (46)
- Cytological evaluation of biological prognostic markers from primary breast carcinomas (1997) (44)
- Expression of estrogen receptor variants (1993) (43)
- Biomarkers in early breast neoplasia (1993) (43)
- Treatment decisions in axillary node-negative breast cancer patients. (1992) (42)
- Biomarker profile and genetic abnormalities in lobular carcinoma in situ (2005) (41)
- Ki 67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer : Results From the American College of Surgeons Oncology Group Z 1031 Trial ( Alliance ) (2016) (40)
- Problems and solutions in the evaluation of hormone receptors in breast cancer. (2008) (40)
- Improved methods of estimating mitotic activity in solid tumors. (1992) (39)
- Prognosis and treatment decisions in patients with breast cancer without axillary node involvement (1992) (37)
- Response: Location of BRCA1 in Human Breast and Ovarian Cancer Cells (1996) (36)
- HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients (2016) (35)
- Re-evaluating Adjuvant Breast Cancer Trials: Assessing Hormone Receptor Status by Immunohistochemical Versus Extraction Assays (2007) (35)
- Loss of heterozygosity events impeding breast cancer metastasis contain the MTA1 gene. (2001) (34)
- Mastectomy and oophorectomy by menstrual cycle phase in women with operable breast cancer. (2002) (32)
- Anaplastic large cell (Ki-1) lymphoma with histiocytic phenotype simulating carcinoma. (1990) (32)
- Immunohistochemical studies of early breast cancer evolution (2004) (32)
- The estrogen paradox (2007) (31)
- Re: Mastectomy and Oophorectomy by Menstrual Cycle Phase in Women With Operable Breast Cancer (2002) (31)
- Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ (2019) (31)
- Loss of heterozygosity at D14S62 and metastatic potential of breast cancer. (1999) (31)
- The role and prognostic significance of p53 gene alterations in breast cancer (2004) (29)
- p53 mutation and tamoxifen resistance in breast cancer. (1995) (28)
- A role for estrogen-receptor variants in endocrine resistance (1995) (28)
- Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer (2010) (28)
- Should immunohistochemical examination replace biochemical hormone receptor assays in breast cancer? (1993) (27)
- WAF1/CIP1 protein expression in human breast tumors (1997) (24)
- Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer (2017) (23)
- ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer. (2010) (21)
- Enhancement of immunoreactivity among lymphoid malignant neoplasms in paraffin-embedded tissues by refixation in zinc sulfate-formalin. (1991) (20)
- Biomarkers in benign breast disease: risk factors for breast cancer. (1998) (20)
- The p53 tumor-suppressor gene in human breast cancer. (1994) (19)
- The ER-positive / PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain (2004) (18)
- Timing of adjuvant surgical oophorectomy in the menstrual cycle and disease-free and overall survival in premenopausal women with operable breast cancer. (2015) (18)
- Immunohistochemistry on Histological Sections from Small (50 mg) Samples of Pulverized Breast Cancer (1993) (18)
- Response and resistance to the endocrine prevention of breast cancer. (2008) (15)
- Prediction of 10-Year Chemotherapy Benefit and Breast Cancer-Specific Survival by the 21-Gene Recurrence Score (RS) Assay in Node-Positive, ER-Positive Breast Cancer – An Update of SWOG-8814 (INT0100). (2009) (15)
- Recessive oncogenes. (1993) (15)
- p53 mutations in gastric and colorectal cancers in Texas Hispanics versus Anglos (2004) (15)
- Glutathione transferase GST pi in breast tumors evaluated by three techniques. (1993) (15)
- Morphologic and Immunophenotypic Markers as Surrogate Endpoints of Tamoxifen Effect for Prevention of Breast Cancer (2005) (15)
- Anergy-like immunosuppression in mice bearing pulmonary foreign-body granulomatous inflammation. (1985) (15)
- FGFR1 amplification and the progression of non-invasive to invasive breast cancer (2012) (14)
- Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer-Clinical Notice (2010) (13)
- JNCCN HER 2 Testing in Breast Cancer : NCCN Task Force Report and Recommendations (2006) (12)
- "Dwarf" estrogen receptor in breast cancer and resistance to tamoxifen. (2009) (11)
- An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors. (2017) (11)
- Estrogen receptor status (ER) determined by immunohistochemistry (IHC) is superior to biochemical ligand-binding (LB) assay for evaluating breast cancer patients (1997) (10)
- Biomarkers predicting recurrence and progression of ductal carcinoma in situ treated by lumpectomy alone. (2010) (10)
- Breast cancer: noninvasive and special situations. (2010) (9)
- Advances in Brief A Hypersensitive Estrogen Receptor-a Mutation in Premalignant Breast Lesions 1 (2000) (9)
- HER-2/ neu Oncogene Amplification and Expression in Human Mammary Carcinoma (1991) (9)
- Intra-mammary Ductal Transplantation: A Tool to Study Premalignant Progression (2012) (8)
- Molecular Biomarkers of Risk in Premalignancy and Breast Cancer Prevention (2011) (6)
- Preparation of Paraffin Blocks and Sections Containing Multiple Tissue Samples Using a Skin Biopsy Punch (1990) (6)
- Scientific Statement: Postmenopausal Hormone Therapy (2010) (6)
- ER expression is not bimodal in breast cancer. (2005) (6)
- Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study (2005) (6)
- The utility of conventional and molecular pathology in managing breast cancer (2008) (5)
- The origins of oestrogen receptor negative breast cancer (2007) (5)
- Mutation and Tamoxifen Resistance in Breast Cancer ’ (2005) (5)
- Predictive and Prognostic Marker Testing in Breast Pathology: Immunophenotypic Subclasses of Disease (2012) (4)
- A poor prognosis ER and HER2-negative, nonbasal, breast cancer subtype identified through postneoadjuvant endocrine therapy tumor profiling (2008) (4)
- RNA from air-dried frozen sections for RT-PCR and differential display. (1996) (4)
- The Progression of Pre-invasive to Invasive Cancer (2011) (3)
- Fixation time does not affect expression of HER2/neu. (2011) (3)
- Molecular Pathology of Breast Cancer (2013) (3)
- The Assessment of Hormone Receptors in Breast Cancer by Immunohistochemistry (2005) (3)
- Introduction: Models of Premalignant Breast Disease (2000) (3)
- Immunohistochemical Biomarkers in Breast Cancer (1999) (3)
- Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancer (2005) (2)
- Re: The influence of menstrual cycle phase on surgical treatment of primary breast cancer: have we made any progress over the past 13 years? (2002) (2)
- Determining Which Patients with Ductal Carcinoma In Situ Should Receive Tamoxifen (2012) (2)
- A clinical trial to assess biomarker modulation by tamoxifen in normal and premalignant breast tissue (2001) (2)
- Expression and Prognostic Significance of the HER-2/neu Oncogene During the Evolutionary Progression of Human Breast Cancer (1991) (2)
- Ductal Carcinoma In situ and the Emergence of Diversity during Breast Cancer Evolution. Commentary (2008) (2)
- American Society of Clinical Oncology/College ofAmerican Pathologists guideline recommendations forimmunohistochemical testing of estrogen andprogesterone receptors in breast cancer (2010) (1)
- Abstract A55: Genes regulating the progression of human ductal carcinoma in situ to invasive breast cancer (2011) (1)
- Recessive oncogenes (1)
- Abstract P3-05-10: The development of a standardized Ki-67 assay for the ALTERNATE trial: An experience in academic investigational device development (2013) (1)
- Whole genome sequencing to characterize luminal-type breast cancer. (2012) (1)
- A comparison of foreign body and hypersensitivity granuloma formation in the mouse: kinetic development, anergy, angiotensin converting enzyme levels, and response to captopril therapy. (1991) (1)
- DifferentiallyExpressedGenesRegulatingtheProgressionof Ductal Carcinoma In Situ to Invasive Breast Cancer (2012) (1)
- Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer (2023) (0)
- Role for the estrogen receptor in breast cancer evolution (1994) (0)
- Tumor and Stem Cell Biology Differentially ExpressedGenesRegulating theProgressionof Ductal Carcinoma In Situ to Invasive Breast Cancer (2012) (0)
- Tumor C haracteristics a nd C linical O utcome o f T ubular and M ucinous B reast C arcinomas (1999) (0)
- II mage-Detected Breast Cancer : State of the Art iagnosis and Treatment (2005) (0)
- 15 O - Isolation of an estrogen receptor variant with increased activity from premalignant breast lesions (1996) (0)
- Genetic surrogate endpoint biomarkers in early breast neoplasia (1993) (0)
- FGFR1 amplification and the progression of non-invasive to invasive breast cancer (2012) (0)
- Genes Regulating the Progression of Human Ductal Carcinoma In Situ to Invasive Breast Cancer. (2009) (0)
- Association between Ki-67 and histologic grading in Nigerian patients with breast cancer. (2011) (0)
- Abstract LB-423: Whole genome comparisons of pre- and post- aromatase inhibitor treatment in estrogen receptor positive breast cancer (2012) (0)
- EDITORIALS Biomarkers in Benign Breast Disease: Risk Factors for Breast Cancer (1998) (0)
- Methodes et compositions utiles dans le diagnostic et le traitement du cancer du sein (2002) (0)
- Abstract A21: Characterization of the immune environment in the in situ to invasive breast carcinoma transition (2018) (0)
- Methode d'immunohistochimie quantitative et d'hybridation in situ (2006) (0)
- Primer-extension pre-amplification of DNA from paraffin-embedded tissue: Analysis of concurrent breast lesions (1994) (0)
- Is Mutated in a Subset of Advanced-Stage Prostate Cancers 1 (2006) (0)
- Publication of Nearly Identical Articles (1996) (0)
- FGFR 1 amplifi cation and the progression of non-invasive to invasive breast cancer (2015) (0)
- Invasive Breast CancerPractice Guidelines in Oncology (2011) (0)
- Advances in Brief Inhibition of Estrogen Receptor Action by a Naturally Occurring Variant in Human Breast Tumors 1 (2006) (0)
- Histological grading and molecular correlates of ductal carcinoma in situ (DCIS) (1997) (0)
- Immunohistochemistry Testing and Beyond in Breast Cancer (2014) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Donald Craig Allred?
Donald Craig Allred is affiliated with the following schools:
